The hallmarks of CRS, after treating a patient with an agent like an anti-CD3 antibody, are the transient but significant increases in the cytokines TNFα, INFγ, IL-2 and IL-6 (Sathish et al., 2013). This evidence concerns the gene TNF and congenital rubella syndrome.